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Abstract
Background: Around 6% of total deaths are related to alcohol consumption worldwide. Mathematical models are
important tools to estimate disease burden and to assess the cost-effectiveness of interventions to address this
burden.
Methods: We carried out a systematic review on models, searching main health literature databases up to July
2017. Pairs of reviewers independently selected, extracted data and assessed the quality of the included studies.
Discrepancies were resolved by consensus. We selected those models exploring: a) disease burden (main metrics
being attributable deaths, disability-adjusted life years, quality-adjusted life years) or b) economic evaluations of
health interventions or policies, based on models including the aforementioned outcomes. We grouped models
into broad families according to their common central methodological approach.
Results: Out of 4295 reports identified, 63 met our inclusion criteria and were categorized in three main model
families that were described in detail: 1) State transition -i.e Markov- models, 2) Life Table-based models and 3)
Attributable fraction-based models. Most studies pertained to the latter one (n = 29, 48.3%). A few miscellaneous
models could not be framed into these families.
Conclusions: Our findings can be useful for future researchers and decision makers planning to undertake alcohol-
related disease burden or cost-effectiveness studies. We found several different families of models. Countries
interested in adopting relevant public health measures may choose or adapt the one deemed most convenient,
based on the availability of existing data at the local level, burden of work, and public health and economic
outcomes of interest.
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Background
Alcohol is a cross-cutting, harmful factor considered in
the United Nations’ Sustainable Development Goals
(SDG) Agenda 2030, illustrating the issue that disease bur-
den attributable to high consumption should be effectively
addressed: SDG 3.5 aims to “strengthen prevention and
treatment of substance abuse, including narcotic drug
abuse and harmful use of alcohol” [1]. Alcohol consump-
tion has been linked with more than 200 types of injuries
and diseases, including road traffic and domestic acci-
dents, cancer, liver cirrhosis, stroke, alcoholic cardiomyop-
athy and infectious diseases, and it has been estimated
that around 6% of total deaths could be attributable to
alcohol consumption worldwide [2]. The Institute for
Health Metrics and Evaluation (IHME) estimated that in
2016 1.6% of total disability adjusted life years (DALYs)
globally among females and 6.0% among males
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correspond to alcohol-related diseases [3]. A total 174,000
deaths were attributable to alcohol use disorders in that
year in the Global Burden of Disease project [4]. About
12% of global DALYs due to road injuries and 14–18.5%
of those due to self-harm and interpersonal violence are
attributable to alcohol use. Alcohol is also the main risk
factor for death and/or disability among people between
15 and 49 years of age in some regions of the world [3].
Alcohol consumption also generates an important
economic burden [5]. Rehm and colleagues showed that
its weighted average cost was 2.5% of GDP-purchasing
power parity (PPP) among high-income countries (such
as Canada, France, Scotland and United States); also that
its average social cost of was 2.1% of GDP-PPP for some
Asian middle-income countries (like the Republic of
Korea and Thailand), and ranged between 0.45 and
5.44% of GDP in another study [6]. However, the dis-
crepancies in the estimation methods and the cost com-
ponents hinder direct comparisons, suggesting the need
for local-level approaches. This economic toll will in-
crease for LMICs because per capita alcohol consump-
tion in these countries increases as GDP-PPP increases
[7]. However, more precise estimates of the health, eco-
nomic and social impact of alcohol are still lacking for
many countries. Mathematical modelling is one of the
principal methodologies to evaluate the potentiality of
public health interventions through simulation. It has
been increasingly used to evaluate the burden of disease
of conditions and to estimate the cost-effectiveness of
alternative healthcare interventions in order to efficiently
allocate limited resources [8]. The Organization for
Economic Cooperation and Development (OECD) has
carried out an analysis based on a simulation model
showing that several policies against high consumption
of alcohol have also the potential to reduce regular and
episodic drinking and alcohol dependence up to 5–10%
[9]. Even the most expensive alcohol policies have shown
favourable cost-effectiveness profiles. For example, brief
physician advice (assuming 50% coverage), or raising
taxes to alcohol have shown incremental cost-
effectiveness ratios well-below one per capita GDP for
many countries in all continents in a recent WHO re-
port [10].
This would lead countries towards achieving the vol-
untary goal of reducing harmful alcohol consumption by
10% by 2025, adopted by the World Health Assembly in
2013 as part of the Global Noncommunicable Diseases
(NCD) surveillance framework [11]. The ability of gov-
ernments to design, implement and evaluate compre-
hensive prevention strategies, combining the strengths of
different approaches, is critical to achieve this goal. In
this regard, simulation models have many strengths [12].
They can synthesize available evidence and provide new
evidence to inform decision making in areas where
direct empirical research can be difficult or impossible,
they can also extrapolate beyond data observed in pri-
mary research. However, they require multiple assump-
tions and depend on a variety of input parameters,
especially epidemiological and economic ones, some of
which may be of limited quality or even non-existent in
many countries. That is why this study sought to estab-
lish which alcohol attributable disease burden and cost-
effectiveness models have been tested in the world,
based on a systematic review of the literature. Our ob-
jective was hence, to depict the main methodological
characteristics of these models to inform researchers
and technical teams in ministries of health their charac-
teristics and pros and cons; thus, facilitating the choice
of the model to use, adapt or develop in each country or
region with the available data, in order to promote pub-
lic policies aimed at reducing alcohol related problems.
Methods
We followed the Meta-analysis Of Observational Studies
in Epidemiology (MOOSE) [13] and Preferred reporting
items for systematic reviews and meta-analyses
(PRISMA) [14] statements to conduct and report the
present systematic review. The present work is part of a
larger multicentre study funded by the Ministry of
Health of Argentina. The research question was to
identify and evaluate those models to estimate popula-
tion disease burden related to alcohol consumption, and
cost-effectiveness of public health interventions aimed at
reducing it. Due to the exploratory nature of this work a
traditional PICO question format was not possible. We
undertook a systematic search up to July 2017 in the
following biomedical bibliographic databases: Medline,
LILACS, ECONLIT, Psych Info, EMBASE and
COCHRANE. Details about the electronic searches
carried out are provided in the Additional file 1. We also
hand-searched reference-lists of systematic reviews (SR)
of models and health economic evaluations for
additional information, and did prospective citation
tracking.
Selection process and eligibility
Pairs of reviewers independently selected articles initially
by title and abstract and subsequently evaluated the full
texts. Discrepancies were solved by consensus of the
whole team. For the eligibility of articles the following
inclusion criteria were established: 1) epidemiological
models that explore alcohol related disease burden
reporting attributable deaths and at least one of the
following outcomes: DALYs, Quality-Adjusted Life Years
(QALYs), or Years of Life Lost (YLLs), and 2) model-
based economic evaluations of health interventions or
policies, implemented or implementable at the city, state,
or national level that included the aforementioned
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outcomes. In addition, studies fulfilling the previous cri-
teria needed to be also comprehensive with regards to
the attributable diseases or conditions included and
cover at least three of these large areas: injuries by exter-
nal causes, mental illness, gastrointestinal disease, car-
diovascular or cancer.
The exclusion criteria were: 1) Publishing date before
the year 2000, 2) Cost-only studies, 3) Model or study
not specific to alcohol, or that assessed several effects
and alcohol was not specified separately (e.g. considered
several psychoactive substances), 4) only analysed sub-
groups (i.e. by age or sex), and/or did not refer to gen-
eral population, 5) economic evaluations based only on
randomized controlled trials (piggy back studies).
Methodological quality evaluation and data extraction
Pairs of reviewers independently extracted data using a
previously piloted data extraction form and assessed the
risk of bias in the included studies using Cochrane’s
Covidence software [15]. In case of disagreement, it was
resolved by consensus. In case of difficulty to reach a
consensus, a third author made the final decision. In
order to evaluate the quality of each family of models
the specific tool proposed by Bhuia et al. [16] was
adapted. This tool involved an independent evaluation of
the strengths (five domains) and limitations (five do-
mains) of the ‘models’ based on their structure, specifi-
cations, assumptions, sensitivity analysis, validation,
treatment of missing data, theoretical basis, incorpor-
ation of confounding factors and temporal window, and
methodological limitations. Additionally, this tool was
supplemented with a list of additional features agreed
upon by the working group. Bhuia’s original tool is pre-
sented in the Additional file 1. We did not present the
results of the risk of bias assessment at the individual
study level because we aimed to assess and expose the
methodological characteristics, strengths and limitations
of the aggregate model conceptual families, with this
very comprehensive tool.
Following Brennan et al. [12] we defined a model as a
formal quantified comparison, synthesizing sources of
evidence on costs and benefits, in order to identify the
best option for decision makers to adopt. This author
proposed a taxonomy of models [12] according to some
dimensions that could be considered, such as cohort or
individual level counts, and the allowance of interaction
between individuals. We simplified this taxonomy
grouping relevant articles into model families by means
of their common central methodological approaches.
Results
The flow of the systematic review is detailed in Fig. 1
(scheme according to the PRISMA checklist for system-
atic reviews).
We identified a total of 4295 references from the
bibliographic databases and five more through grey lit-
erature, for further screening. Of them, 4247 remained
after leaving out duplicates, and 137 were selected for
full-text screening. We finally included sixty-three
articles which were scrutinized in depth and grouped by
their shared central methodological features, for repro-
ducibility reasons. We identified a)state transition
models, i.e., those decision-analytic modelling including
Markov model cohort simulations and individual-based
(first-order Monte Carlo) microsimulations [17], b)
multistage life table models capable of estimating inci-
dence, prevalence, remission, mortality based on popula-
tion life tables, which predict the demographic
consequences derived from introducing public health in-
terventions [18], and c) population attributable and
preventable fraction modelling studies, in which risk fac-
tors are selected based on the level of evidence for a
causal relationship, relevancy of the risk factors for
population health, availability and quality of population-
representative data, and if the risk factors are avoidable
[19]. Within these three broad families, comprising 70%
of the publications identified in the systematic review
(44 of 63), we describe more in depth the most well-
known or utilized models, i.e. those with a larger number
of citations, more extensively used, and with technical
reports or papers describing their development and speci-
fications. (See Table 1.)
Most studies pertained to the “Attributable fraction-
based models” family (n = 29, 46.0%), followed by state
transition one (n = 16, 25.4%) and the life-table family
(n = 4, 6.3%). Some of the studies run at the individual-
level (microsimulations) while others assessed aggregate
populations or cohorts. None explored the interaction of
either individuals, or multiple individual behaviours or
risk factors. None of them was a discrete event
simulation.
Briefly they encompass the following:
State transition models include three main specific
models: the Sheffield Alcohol Policy Model, the Dynamic
Modelling for Health Impact Assessment (Dynamo-HIA)
model and the Chronic Diseases Model. Transitions in
disease-related states were more commonly modelled than
risk-factor-related behaviors transitions (for example
between various levels and patterns of alcohol use). The
Sheffield Alcohol Policy Model (SAPM) provides esti-
mates of the effectiveness and cost-effectiveness of policies
to reduce alcohol consumption. It has been used in Great
Britain, Canada and multiple European countries to exam-
ine the potential impact of pricing and promotion policies;
minimum unit prices and restrictions on discounts; regu-
lation of alcohol output density and licensing hours;
advertising controls; alcohol screening and brief interven-
tion strategies. It is one of the most complete and complex
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models we identified. It includes different sub-models:
those specific to the intervention, and the main simulation
model of expected risk consumption, which is a Markov-
type chain that models the annual risk of death for each
alcohol-related illness. The results of the model provide
estimates of: changes in alcohol consumption for different
subgroups of the population; changes in the incidence of
various alcohol-related injuries, including health condi-
tions, crime, unemployment and absence due to illness;
direct costs to health services or to the police, as well as
costs associated with changes in the quality of life of
people (for example, of alcohol-related illnesses or being a
victim of a crime). It allows analysing particular subgroups
of interest, such as dangerous young drinkers, moderate
low-income drinkers or high-income women who drink
alcohol. There are many publications that describe the ex-
perience with the use of SAPM [20–31, 72].
The DYNAMO-HIA model can be used to quantify
the impact of changes in risk factors in multiple diseases,
comparing a reference scenario with one or more inter-
vention scenarios. It is a Markov type mathematical
model that allows to simulate the expected events in a
population from different risk factors distribution sce-
narios. The model requires data on: 1) the population
(size, births, survival, weight of the DALYs); 2)
incidence, prevalence, relative risks and mortality of the
different conditions that it evaluates; 3) prevalence of
risk factors and risk categories for the assessed risk
factor, in this case alcohol. As results of the model,
information is obtained on the number of deaths,
disease-free life expectancy, number of cases of cardio-
vascular disease, stroke, diabetes, lung cancers, oral cav-
ity, oesophageal, colorectal and breast, and COPD. It has
been used in countries of the European Union to esti-
mate the impact of different scenarios of price increase
through taxes.
Lhachimi et al. [32, 33] published a dynamic modelling
tool, named DYNAMO-HIA-A for generic health impact
evaluations, used for alcohol. The generic model meets
three technical criteria (real population, dynamic projec-
tion, explicit risk factors states) and three usability
criteria (modest data requirements, results of enriched
models, generally accessible).
Tariq et al. in 2009 [73] published a cost-effectiveness
analysis to assess the effects of a screening and brief
intervention (SBI) for excessive alcohol consumption
(compared to the current state of not doing so) in the
primary care setting, in The Netherlands, using the
Chronic Disease Model. It incorporated the perspective
of health. It is able to establish the costs of medical care
Fig. 1 Flow of studies in the review
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Table 1 Main model families and their characteristicsa
State transition models (Markov) Life tables
models
Attributable fraction models
Model specifications Sheffield DYNAMO-HIA Chronic disease model (CDM) Life tables
models























Time Frame Lifetime 10 years Lifetime Lifetime Lifetime Lifetime
Main outcome Disease Burden, cost-
effectiveness





























Key references [20–31] [32, 33] [34, 35] [36–39] [40–67] [68–71]




Observed in all studies Observed in all studies Observed in all studies Observed in
all studies





Reported or referenced Reported or referenced Sometimes reported Sometimes
reported




Yes Yes Yes Yes Yes Yes
Assumptions Reported in all studies Reported in all studies Reported in all studies Reported in
all studies











Does not apply Reported in all studies Sometimes reported Frequently
reported






Reported in all studies Reported in all studies Frequently reported Frequently
reported













Table 1 Main model families and their characteristicsa (Continued)
State transition models (Markov) Life tables
models
Attributable fraction models
Model specifications Sheffield DYNAMO-HIA Chronic disease model (CDM) Life tables
models
















Not available Not available Not available Not available Not available Not available
Model Theoretical
framework
Reported in all studies Reported in all studies Frequently reported Frequently
reported





Data Sources Reported in all studies Reported in all studies Reported in all studies Frequently
reported




Reported in all studies Reported in all studies Frequently reported Frequently
reported





Does not apply Reported in all studies Sometimes reported Frequently
reported




Reported in all studies Reported in all studies Reported in all studies Reported in
all studies










Reported in all studies Reported in all studies Reported in all studies Frequently
reported





Not reported Not reported Reported in all studies Frequently
reported




Not reported Not reported Not reported Not
reported
Sometimes reported Not reported
Calibration with
real data
Does not apply Not reported Not reported Not
reported
Not reported Not reported
Validation If model validation
was undertaken
Frequently reported Not reported Not reported Not
reported





Reported in all studies Not available Reported in all studies Frequently
reported
Frequently reported Reported in all
studies
Missing data If there is some
explanation












Table 1 Main model families and their characteristicsa (Continued)
State transition models (Markov) Life tables
models
Attributable fraction models
Model specifications Sheffield DYNAMO-HIA Chronic disease model (CDM) Life tables
models





If the model is
released before




Reported in all studies Not available Not available Reported in
all studies















Reported in all studies Not available Not available Not available Sometimes reported Reported in all
studies





Reported in all studies Reported in all studies Frequently reported Frequently
reported









Reported in all studies Reported in all studies Reported in all studies Frequently
reported
Frequently reported Reported in all
studies




Reported in all studies Reported in all studies Not available Not available Reported in all studies Reported in all
studies
Reproducibility If data are available Frequently reported Reported in all studies Not available Not available Sometimes reported Reported in all
studies
If the codes are
available




Not available Reported in all studies Not available Not available Frequently reported Reported in all
studies
Area of application UK Europe National National Multiple areas National




Holland Australia Reported in all studies Various












Table 1 Main model families and their characteristicsa (Continued)
State transition models (Markov) Life tables
models
Attributable fraction models
Model specifications Sheffield DYNAMO-HIA Chronic disease model (CDM) Life tables
models
Comparative Risk Assessment WHO-Choice
(data by sex) (data by sex) (data by sex) specified (data by sex) studies (data
by sex)
Age subgroups Reported in all studies Over 16 years. Categories
every 10 years.
















Not reported No Not reported Not
reported




consumed gr / day
Moderate (up to 21 units
[10 ml of neat alcohol] per
week for men and 14 units
for women) /Hazardous
(21–50 units men, and
14–35 women and Harmful
(more than 50 units for
men and more than 35 for
women)
Alcohol consumption is
measured by five categories
of daily intake of
grams of pure alcohol: 0–<
0.25 g/d, 0.25–< 20 g/d,
20–< 40 g/d, 40–< 60 g/d,
≥60 g/d.
for women: abstinence (no
alcohol consumption), moderate
(less than two standard drink
units per day), excessive
consumption (between two and
four per day), and dangerous
consumption (more than four per
day), for men: abstinence (same),
moderate consumption (fewer
than four per day), excessive
consumption (between four and
six per day) and dangerous









Drinker I (females 0–19.99 g
pure alcohol daily, males
0–39.99 g pure alcohol),
Drinker II (females 20–39.99 g
pure alcohol, males 40–59.99 g
pure alcohol) and Drinker III
(females ≥40 g pure alcohol,
males ≥60 g pure alcohol).
Heavy or
Dangerous (>
20 g per day
for women



























Reported in all studies Reported in all studies Reported in all studies Reported in
all studies





Reported in all studies Reported in all studies Reported in all studies Reported in
all studies
















Table 1 Main model families and their characteristicsa (Continued)
State transition models (Markov) Life tables
models
Attributable fraction models
Model specifications Sheffield DYNAMO-HIA Chronic disease model (CDM) Life tables
models






Reported in all studies Not reported Sometimes reported Reported in
all studies





Reported in all studies Not reported Not reported Reported in
all studies






Reported in all studies Not reported Not reported Not
reported
Not reported Not reported
Incorporates quality
of life / disability
(DALYs, QALYs)
Reported in all studies Not available Reported in all studies Reported in
all studies
Reported in all studies Reported in all
studies












and the cost for QALYs earned after the intervention. It
is a non-specific mathematical model for alcohol. The
model provides a simulation of a real-life population. It
also incorporates the effectiveness of brief interventions.
However, the specific group of diseases attributable to
alcohol included was unclear. Van den Berg in 2008 [35]
had already used this model, but for Sweden, and instead
of SBIs, it incorporated the increase in alcohol taxes, de-
termining that it results in a cost-effective intervention
in that country.
Regarding life table models, Cobiac et al. [72] pub-
lished a study in which they evaluated the cost-
effectiveness of eight interventions to reduce the damage
attributable to alcohol and determine the optimal inter-
vention combination. These included taxes, advertising
bans, increasing the legal minimum drinking age, licens-
ing controls for hours of operation, brief intervention
(with and without general medical telemarketing and
support), drinking driving campaigns, random testing
and residential treatment for alcohol dependence (with
and without naltrexone). This study was conducted for
the population of Australia in 2003. Health outcomes
were assessed using DALYs, a multi-cohort and multi-
state approach based on life tables to determine changes
in disease incidence, prevalence and mortality, and
alcohol-related injuries due to each intervention. It is
specially designed to cope relatively easily with a large
number of diseases simultaneously, allowing also for co-
morbidities [74]. Byrnes et al. in 2010 also used the life-
table model to estimate the benefits of tax increases on
alcoholic beverages in Australia [72].
As regards attributable fractions models, comparative
risk analyses (CRA) were developed by the WHO work-
ing group, among others. This method allows estimating
and comparing the burden of disease and mortality at-
tributable to different risk factors. In the case of alcohol,
the exposure (prevalence) of different forms of con-
sumption (average and episodic heavy drinking) is con-
sidered, all the health conditions related to alcohol, its
prevalences’, and the relative risks of these forms are
identified. With these data, the attributable population
fractions are estimated, generally according to sex, age
groups and regions, comparing the current exposure
with the counterfactual exposure (usually lifetime ab-
stention). These analyses estimate the burden of disease
attributable to alcohol in a region, commonly in the
form of DALYs.
The WHO-Choice Model has been called Generalized
Cost-Effectiveness Analysis (GCEA) and is based on the
WHO Choosing Cost Effective Interventions (WHO
CHOICE) project. Methodologically, it can also be con-
sidered a continuation of the Comparative Risk Assess-
ment but it also uses state transitions. In the GCEA, the
cost-effectiveness of certain interventions (or their
combinations) is evaluated through a population status
transition model (POPMOD). It compares scenarios in
which different interventions are implemented that run
for 10 years, and others without them (natural history).
These scenarios are usually projected over a 100-year
horizon. The data required for the model are: prevalence
of risk exposure, associated morbidity and mortality
rates, relative risks, remission rates, effect sizes of each
intervention to be modelled, and costs of implementing
each intervention for 10 years. The effectiveness of each
scenario is frequently measured in DALYS, and the cost-
effectiveness by the cost per DALY avoided.
Finally, we identified a number of miscellaneous
models, not fitting in the above-described groups. Chik-
ritzhs et al. in 2002 [75] for example, described a model
for calculating estimates of the number of deaths caused
by alcohol. They describe a common approach for both
acute and chronic conditions related to alcohol. In the
absence of consistent measurements of the prevalence of
risky alcohol consumption from national surveys, they
recommend the use of per capita consumption data in
order to adjust the etiological fractions of the population
consuming alcohol over time and between regions. The
parameters evaluated were mainly of sensitivity and
specificity of screening, and effectiveness of brief inter-
ventions. Solberg et al. in 2008 [76] published a system-
atic review and economic evaluation based on models
they denominate “algebraic model”. The main parame-
ters evaluated were adherence, effectiveness, lifetime
burden of diseases attributable to alcohol; and costs.
Navarro et al. published in 2011 a cost-effectiveness
study on brief interventions to prevent the misuse of al-
cohol in rural areas of Australia. They compared nine
detection scenarios with the current state. Its parameters
are related to consumption and Alcohol Use Disorders
Identification Test (AUDIT) questionnaire levels based
on the analysis of a survey in 1540 subjects in rural
Australia. Doran et al. in 2013 [77] examined the eco-
nomic and health implications of changing alcohol taxes
in Australia through a model-based economic evaluation
that combines tax aspects with epidemiological model-
ling, for multiple alcohol cohorts, using parameters such
as taxes, consumption and elasticity. Lewsey et al. in
2016 [78] developed an alcohol policy model that calcu-
lates life years, quality adjusted life years (QALYs), and
health care costs using AUDIT and other risk factors’
screening. Its parameters are based on Scottish surveys
and morbidity records. Finally, Chung et al. in 2014 [79]
explored the effects of age, period and cohort on
alcohol-related mortality in relation to changes in gov-
ernment taxes on alcohol. Its parameters were retro-
spective mortality data of more than 30 years between
1981 and 2010 in Hong Kong. Alcohol-related mortality
was evaluated from chronic causes, acute causes, all
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causes (chronic and acute) and causes 100% attributable
to alcohol.
The central features of these families of models of dis-
ease burden or cost-effectiveness, and their methodo-
logical quality appraisal are presented in the table.
Discussion
Through this systematic review we identified 63 studies
that described and reported relevant results using a var-
iety of models to assess the burden of disease and / or
the cost-effectiveness of interventions for alcohol con-
trol. These models included comparative risk assess-
ments, life table models, and state transition ones, as
broad categories.
Our results show that a variety of alcohol consumption
specific modelling approaches have been used to under-
stand its associated burden. This observation is in agree-
ment with a recent review of modelling structures for
interventions on alcohol and other drugs’ dependence,
published by Hoang et al., and using Brennan’s tax-
onomy [80]. Also coincident with our findings, the com-
prehensive OECD report, which summarized the results
of the economic evaluations of alcohol policies available
in 2015, retrieved most analyses found in our study [9].
However, our review incorporates many descriptive ele-
ments regarding their reporting and conduction quality,
through the modified Bhuia tool to assess economic
evaluations’ quality. We observed that some of the evi-
dence is based on the WHO-CHOICE model developed
by the World Health Organization (WHO) in the early
2000s. In addition, the Australian ACE prevention pro-
gram (corresponding to the family “life tables models” in
our study), the Chronic Disease Model (related to the
“comparative risk assessment”), the SAPM (“state transi-
tion models”) and Dynamo-HIA were used in many
countries. We incorporated a miscellaneous category of
important models which did not constitute conceptual
and application units, clearly separated from the rest [9].
Some of the models like WHO-CHOICE, Dynamo,
SAPM and CDM developed special software packages or
webpages, where end users can enter parameters for dif-
ferent settings or countries and get results. Many of
these evaluations characterized the effect of price in-
creases -mainly through taxing-, advertising restrictions,
and prohibitions as the three most cost-effective policies
to reduce alcohol-related harm. Short interventions
within the health system, have also shown to be efficient,
but costlier than population strategies, and for some pol-
icies such as school programs and media campaigns, ef-
fectiveness is not fully established.
The SAPM model allows to have a wide spectrum of
consequences attributable to excessive alcohol consump-
tion since it contemplates, not only direct damage to
health, but also the social consequences of consumption,
including accidents and injuries, as well as impact on the
economy of individuals and the society (indirect costs).
It was designed and adapted to evaluate the impact and
cost-effectiveness of multiple interventions to control
alcohol consumption so it’s very versatile. However, it
requires a great deal of information with a high level of
discrimination that can be very difficult, even impossible,
to obtain in many countries. DYNAMO-HIA has a user-
friendly graphic interface, and employs a model structure
that ensures accurate simulation using epidemiological
evidence while having modest data needs. It allows sensi-
tivity analyses, although not probabilistic ones. It is avail-
able for free download and includes a data set covering a
large number of countries. However, results do not
account for broad effects that a change in alcohol con-
sumption may have on global population health. CDM
has been used for projections of alcohol consumption and
disease prevalence, estimates of health-adjusted life ex-
pectancy and cost-effectiveness analysis but not to capture
societal costs and consequences. It has a limited range of
attributable diseases. Also, long term effectiveness of in-
terventions, needed as a model parameter might be diffi-
cult to ascertain. Life table models are based on widely
available data in most countries (mortality and population
life tables), and by incorporating incidence, prevalence,
and other natural history data, can assess the conse-
quences of different public health interventions, usually
estimating burden (in DALYs) and healthcare system
costs. They are somewhat less complex than other model
families and less “data hungry”, though are less suitable or
easily adaptable if focusing on non-health outcomes, or
wider societal costs. Comparative risk assessments’ (CRA)
main advantage is that it allows to model and compare
multiple diseases and risk factors simultaneously. When
used to model alcohol burden of disease or interventions
to address it, it considers the damage from different levels
of exposure including volume, pattern, or even context of
drinking. On the other side, it is unable to model interac-
tions, and it might require important amounts of data,
that may not be available for all regions or countries. Fi-
nally, the WHO CHOICE model is part of a larger and
well-known project that was used to estimate disease bur-
den and cost-effectiveness of multiple conditions and in-
terventions in different regions of the world, and therefore
an advantage is that much of the information required by
the model may be readily available. As with other “gen-
eric” models, it is not properly designed to measure non-
health outcomes, so it has a limitation to capture certain
societal costs and effects falling outside the boundaries of
the health system.
Similar reviews of modelling of cost-effectiveness or dis-
ease burden have been done in various areas of public
health. For example, in smoking cessation [81], weight
management interventions [82] and tuberculosis screening
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[83], state-transition Markov models were coincidently
the most frequently used method. A population-scale
simulation modelling approach can provide a solid basis
to evaluate the relative effectiveness and cost-effectiveness
of a range of alcohol prevention and control strategies,
overcoming the limitations of other approaches, and pro-
viding constant estimates of inputs from resources, costs
and results. A case-based microsimulation approach offers
the best option for modelling realistic individual life tra-
jectories, considering the heterogeneity in populations and
individual behaviours that can influence alcohol harm, as
well as the relative effectiveness of the policies in popula-
tion groups. These models capture the complex set of in-
terrelations between the previous and current use of
alcohol, its demand, and the health, social and economic
consequences it causes.
A limitation of the present work may be the simplifica-
tion of the classification of modelling approaches into
“big” families, which may not reflect the real choices
countries could count on, based on the model aspects
and the real-world complexity. Also, other aspects of
economic evaluations such as perspectives of costs and
benefits, or discounting, were not evaluated. Despite
these limitations, we have provided a very comprehen-
sive picture of the state-of-the-art in public health alco-
hol modelling. We have critically appraised studies with
respect to the appropriateness and quality of the model-
ling aspects.
The significant burden of disease attributable to alco-
hol consumption, and the associated economic and so-
cial damage, warrants the debate on possible public
policies with the aim of preventing and reducing prob-
lematic consumption of alcoholic beverages. Among
these measures, the increase in the prices of alcoholic
beverages through taxes with the intention of reducing
their affordability is one of the most cost-effective inter-
ventions [10, 84–87].
Decision tree modelling may not be sufficient for
evaluating treatments for alcohol, and we did not iden-
tify this type of model fulfilling our inclusion criteria.
The state transition modelling could be sophisticated
enough to capture many of the potential developments
in a disease process through the use of a series of health
states. It can accommodate the time dimension, as indi-
viduals move over time in different states and also depict
the heterogeneity of cohorts by allocating them into
relevant (although limited) groups. However, it relies on
many simplifications, and -especially in the case of co-
hort state transition models- cannot add past events and
personal attributes in determining transition probabil-
ities, nor allow participants to transit to the next state at
different time intervals. Individual based models repre-
sent a powerful tool as it is possible to simulate multiple
events and incorporate subjects’ “histories”, but they
require a larger number of parameters and may be com-
putationally intensive. When evidence is needed to move
forward alcohol public health decisions, which may de-
mand substantial budget allocation, a complex model
would be preferable in case several complex strategies
are being considered. The choice of the most adequate
modelling approach, time frame and perspective of costs
and benefits useful for a country may change the model-
ling results and policy implications significantly. Coun-
tries should carefully consider the availability of existing
data at the local level, as well as the type of interventions
desired to be implemented. Future evaluations should
continue to identify the variety of techniques for model-
ling public health interventions to counter alcohol haz-
ardous consumption.
Conclusions
Our systematic review of alcohol attributable disease bur-
den and cost-effectiveness models shows extensive litera-
ture exists on the subject. We categorized the relevant
models identified into three main families according to
their core methodological aspects -state transition models
(both individual level and cohort-based); life-table models;
and attributable fraction models-. All include some more
complex and “data hungry” specific structures, as well as
some less complex and data-intensive ones. We incorpo-
rated many descriptive elements of their quality of report-
ing and conduction. The summary information reported
in our paper can be helpful for researchers and decision
makers planning to undertake this type of studies, in the
light of local data availability and interventions desired to
be tested.
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